Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06153251 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
A Phase 1 study of Relapsed and/or Refractory Multiple Myeloma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 187
- Enrollment target
- 19
- Study locations
NCT06153251: Recruiting Phase 1 study of Relapsed and/or Refractory Multiple Myeloma, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
NCT06153251 is a Phase 1 study of Relapsed and/or Refractory Multiple Myeloma that is actively recruiting participants, run by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. The registered enrollment target is 187 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (212% higher). The trial reports 19 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06153251, a Phase 1 study of Relapsed and/or Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 187 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG BMS-986453
Study Locations (19)
Other
- Hôpital Saint-Louis - Paris
- Universitaetsklinikum Koeln - Cologne
- Universitaetsklinikum Heidelberg - Heidelberg
- Universitaetsklinikum Wuerzburg - Würzburg
- Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca - Salamanca
California
- City of Hope Comprehensive Cancer Center - Duarte
- UCSF Helen Diller Medical Center at Parnassus Heights - San Francisco
- Stanford University Medical Center - Stanford
New York
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Local Institution - 0008 - Nashville
- Tennessee Oncology - Nashville
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- Colorado Blood Cancer Institute - Denver
Connecticut
- Yale Cancer Center - New Haven
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2024-01-23 |
| Est. Completion | 2030-05-02 |
| Phase | Phase 1 |
What NCT06153251 shows while recruiting
NCT06153251 is an interventional study that assigns participants to a tested intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (212% higher).
The record links to 1 condition, with Relapsed and/or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT06153251 lists 19 locations in 11 states (Other, California, New York).
Frequently Asked Questions
What is clinical trial NCT06153251 about?
NCT06153251 is a clinical study titled "A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma". The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
What is the current status of trial NCT06153251?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 187 participants. The study started on 2024-01-23. Estimated completion is 2030-05-02.
What conditions does trial NCT06153251 study?
This clinical trial studies the following conditions: Relapsed and/or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT06153251?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), BMS-986453 (DRUG).
Who is sponsoring clinical trial NCT06153251?
This trial is sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06153251 being conducted?
This trial has 19 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06153251's enrollment target sits among peer trials
187 290th of 2000 higher than 1,710 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06254898 · 187 participants · NA
Use of Incentives for Stressful Medical Procedures
- NCT07062237 · 187 participants · NA
A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence
- NCT07217574 · 187 participants
Program in Oncology for Tribal Health Systems.
- NCT07306559 · 187 participants · Phase 1
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI